DOCSLIB.ORG

Venture Capital Funding, Second Quarter 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Venture Capital Funding, Second Quarter 2014 Venture Capital Funding Survey, Second Quarter 2014 VENTURE CAPITAL FUNDING, SECOND QUARTER 2014 This is a listing of many of the Bay Area firms that received venture capital financing between April 1 and June 30, 2014. Most of the data was compiled from a survey conducted by PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association in conjunction with The Mercury News. In the case of some investments there may have been other participants in the round who are not credited. Also, the amounts listed may not include all venture funding the company received during the quarter. *Indicates this is a seed or first-round infusion of money from venture capitalists. These companies may have received money previously from other investors and aren't necessarily startups. BIOTECHNOLOGY / HEALTH Name City Stage Amount Investors Description Acerta Pharma San Carlos Startup/Seed $9,333,000 Frazier Management, Pharma treatments for undisclosed firm cancer and autoimmune diseases Aduro BioTech Berkeley Later Stage $40,602,000 Johnson & Johnson Clinical research services Development, Morningside Technologies, undisclosed firm Advanced Cardiac Santa Clara Expansion $7,300,000 NBGI Private Equity, New Temperature-sensing Therapeutics Enterprise Associates cardiac ablation systems Aldea Pharmaceuticals Redwood City Early Stage $1,000,000 Canaan Partners Pharmaceutical company Alector San Francisco Startup/Seed $3,000,000 Polaris Partners Biotech company Alios BioPharma South San Early Stage $41,000,000 F Hoffmann La Roche AG, Novel medicines for Francisco Novartis Venture Funds, treatment of viral diseases Novo A/S, Sr One, undisclosed firm ARMO Biosciences Redwood City Early Stage $30,000,000 Duff Ackerman & Biotechnology company Goodrich, Kleiner Perkins Caufield & Byers, NanoDimension Management, OrbiMed Advisors Avalanche Biotechnologies* Menlo Park Later Stage $55,127,200 Cowen Capital Partners , Gene therapies for serious undisclosed firma, Venrock eye diseases Page 1 of 30 Venture Capital Funding Survey, Second Quarter 2014 BenVenue Medical Santa Clara Later Stage $40,000,000 Domain Associates, Medical solutions and InterWest Partners, biomaterials for spine undisclosed firm, Versant repair Ventures Catalyst Biosciences South San Later Stage $5,010,000 Essex Woodlands Health Engineers therapeutic Francisco Ventures, Morgenthaler protease products Ventures, Sofinnova Ventures Cenexys San Francisco Early Stage $1,000 Undisclosed firm Pharmaceutical drug development services and research Cervel Neurotech Redwood City Expansion $850,000 Aberdare Ventures, D E Medical device company Shaw & Co Ceterix Orthopaedics Menlo Park Early Stage $18,000,000 5AM Venture Surgical tools for Management, Novo A/S, arthroscopic procedure Versant Ventures Chronix Biomedical San Jose Later Stage $3,329,000 Prairiegold Venture Diagnosis, management Partners of a range of cancers Coherus Biosciences Redwood City Early Stage $4,391,000 Sofinnova Ventures Biologics platform company Coherus Biosciences Redwood City Early Stage $55,633,100 Fidelity Biosciences, Biologics platform Kohlberg Kravis Roberts & company Co., Lilly Ventures, RA Capital Management, Sofinnova Ventures, undisclosed firm, Venrock, Vivo Ventures Counsyl South San Expansion $27,999,900 Felicis Ventures, Gives people access to Francisco Rosemont Seneca vital information about Technology Partners, their bodies undisclosed firm Crown Bioscience Santa Clara Later Stage $26,550,000 Lilly Asian Ventures Contract research service CytomX Therapeutics South San Early Stage $1,423,000 Undisclosed firm Proteolytically-activated Francisco antibodies Earlens Menlo Park Early Stage $3,516,000 Aisling Capital, New Medical device company Enterprise Associates, Eiger BioPharmaceuticals Palo Alto Early Stage $500,000 InterWest Partners Biopharmaceutical company Page 2 of 30 Venture Capital Funding Survey, Second Quarter 2014 Endogastric Solutions San Mateo Later Stage $30,637,800 Advanced Technology Surgery solutions for Ventures, Canaan gastroesophageal reflux Partners, Chicago Growth disease Partners, De Novo Ventures, Foundation Medical Partners, Oakwood Medical Investors, Radius Ventures, ForSight VISION5 Menlo Park Early Stage $15,000,000 Delphi Ventures, H.I.G. Clinical development- Capital, Morgenthaler stage company Ventures, Technology Partners, Versant Ventures Gemmus Pharma San Francisco Expansion $3,300,000 Angels' Forum & the Halo Biotechnology company Fund, BlueTree Allied focused on the Angels, Life Science development of Angels, Tech Coast pharmaceutical product Angels, undisclosed firm, Wilmington Investor Network Geneweave Biosciences San Jose Early Stage $12,000,000 Claremont Creek Ventures, Bacterial detection Decheng Capital, X/Seed platforms Capital Management Guardant Health Redwood City Early Stage $31,500,000 Khosla Ventures, Pejman Cancer test based on Mar Ventures, Sequoia blood samples instead of Capital biopsies Gynesonics Redwood City Later Stage $2,161,000 Advanced Technology Medical devices for Ventures, InterWest uterine fibroids Partners Halo Neuroscience* San Francisco Early Stage $1,500,000 Andreessen Horowitz, Neuroscience-based Kima Ventures SASU, technology for enhancing Softtech VC brain performance Ihear Medical San Leandro Expansion $2,499,900 Aphelion Capital, Web-enabled hearing Lighthouse Capital solutions Partners, undisclosed firm Intuity Medical Sunnyvale Later Stage $4,500,000 Accuitive Medical Therapeutic medical Ventures, Investor Growth devices to monitor blood Capital, Thomas McNerney glucose levels and Partners, U.S. Venture Partners, Venrock Page 3 of 30 Venture Capital Funding Survey, Second Quarter 2014 iRhythm Technologies San Francisco Expansion $17,343,000 Norwest Venture Partners, Engages in the Novo A/S management of cardiac arrhythmia information Jaguar Animal Health San Francisco Early Stage $4,777,000 Bioveda China Fund Health solutions to all animals NexSteppe South San Early Stage $9,658,000 Braemar Energy Ventures Feedstock solutions for Francisco II the biofuels and biobased products industry Nora Therapeutics, Palo Alto Early Stage $18,000,000 Burrill & Co., Novo A/S, Biopharmaceutical Prospect Venture Partners, company Rho Capital Partners, Vivo Ventures Numerate San Bruno Early Stage $8,240,000 Atlas Venture Advisors, Engaged in drug Lilly Ventures Management development Company, undisclosed firm One Medical Group San Francisco Later Stage $40,500,000 Undisclosed firms Personal healthcare services Oraya Therapeutics Newark Early Stage $25,132,000 Domain Associates, Essex Developed a non-invasive Woodlands Health therapy for wet age- Ventures, Scale Venture related macular Partners degeneration Pearl Therapeutics* Menlo Park Startup/Seed $500,000 5AM Venture Management Medical company Powervision Belmont Later Stage $6,000,000 Aisling Capital, Correlation Medical device company Ventures, Venrock Presidio Pharmaceuticals San Francisco Later Stage $12,544,000 Undisclosed firm Anti-infection pharmaceutical company Principia Biopharma South San Early Stage $50,000,200 Mission Bay Capital, Biopharmaceutical Francisco Morgenthaler Ventures, company New Leaf Venture Partners, OrbiMed Advisors, Sofinnova Ventures, Sr One, undisclosed firm Proteus Digital Health Redwood City Later Stage $119,450,000 Undisclosed firm Digital medicines company Page 4 of 30 Venture Capital Funding Survey, Second Quarter 2014 Reflexion Medical* Burlingame Early Stage $6,144,000 Pfizer Venture Biologically guided Investments, Sofinnova radiation therapy system Partners SAS, Venrock SFJ Pharmaceuticals Pleasanton Expansion $9,770,000 Undisclosed firms Specialty pharma company Sonitus Medical San Mateo Later Stage $10,215,000 Abingworth Management, Non-surgical and Arboretum Ventures removable hearing devices Sorbent Therapeutics Sunnyvale Later Stage $6,500,200 Arch Venture Partners, Biopharmaceutical CMEA Development Co., company GeneChem Financial, Novartis Venture Funds, Sofinnova Ventures Spinal Kinetics Sunnyvale Later Stage $33,845,200 De Novo Ventures, HLM Medical device company Venture Partners, Lumira Capital., Scale Venture Partners, Sv Life Sciences Advisers True North Therapeutics South San Early Stage $8,000,000 Baxter Ventures, Biogen Therapies that inhibit the Francisco Idec New Ventures, Kleiner complement system to Perkins Caufield & Byers, treat rare disease MPM Capital, Sr One TWELVE Menlo Park Early Stage $9,076,000 Domain Associates, Medical device incubator Morgenthaler Ventures, Versant Ventures Twist Bioscience San Francisco Early Stage $25,999,800 Applied Ventures, Arch DNA production and drug Venture Partners, Paladin development Capital Management, undisclosed firms Virobay Menlo Park Later Stage $6,000,000 Alta Partners, undisclosed Discovers anti-viral drugs firm Voloagri South San Early Stage $976,000 Avrio Capital Management, Invests in the global Francisco Kleiner Perkins Caufield & vegetable seed industry Byers Page 5 of 30 Venture Capital Funding Survey, Second Quarter 2014 BUSINESS SERVICES Name City Stage Amount Investors Description 6 Sense Insights* San Francisco Early Stage $12,000,000 Battery Ventures, B2B predictive intelligence undisclosed firm, Venrock engine for sales and marketing Adespresso San Francisco Early Stage $800,000 500 Startups, Sierra Maya Software-as-a-service Ventures, undisclosed firm, solution to manage VegasTechFund Facebook advertising AdRoll San Francisco Expansion $70,000,100 Accel Partners & Co., Retargeting marketing Foundation Capital, platform Glenmede Trust Co NA,
Load more

Recommended publications
  • Philadelphia Investment Trends Report
    Venture impact Technology investment in the Greater Philadelphia region Trends and highlights, January 2008 to June 2013 Innovation, investment and opportunity On behalf of EY, Ben Franklin Technology Partners of Southeastern Pennsylvania and the Greater Philadelphia Alliance for Capital and Technologies (PACT), we are pleased to present this review 421 companies of technology investment trends and highlights in the Greater Philadelphia region. $4.1 billion The technology investment community in the Greater Philadelphia region includes a wide variety of funding sources supporting a diverse array of companies and industry sectors. In this report, Total investment since we’ve analyzed more than a thousand investment rounds and January 2008 exits that occurred in the Philadelphia region since 2008 – including investments from venture capital fi rms (VCs), angel investors (Angels), corporate/strategic investors, seed funds, accelerators and other sources of funding. As shown in this report, 2012 reversed a post-recession slowdown in venture funding in Greater Philadelphia, and to date, 2013 has brought a welcome increase in the amount of new funds available at regional investment fi rms. These are positive signs for our region’s technology companies, as are the increasing number of exits via IPO and acquisition, which serve as further validation of the investment opportunities created by our region’s growing technology sector. We encourage you to explore this report, and we hope that it will provide useful insights into the current state of
    [Show full text]
  • RESI Boston Program Guide 09-26-2017 Digital
    SEPTEMBER 26 , 2017 BOSTON, MA Early stage investors, fundraising CEOs, scientist-entrepreneurs, strategic partners, and service providers now have an opportunity to Make a Compelling Connection ONSITE GUIDE LIFE SCIENCE NATION Connecting Products, Services & Capital #RESIBOS17 | RESIConference.com | Boston Marriott Copley Place FLOOR PLAN Therapeutics Track 2 Investor Track 3 & track4 Track 1 Device, Panels Workshops & Diagnostic & HCIT Asia Investor Panels Panels Ad-Hoc Meeting Area Breakfast & Lunch DINING 29 25 30 26 31 27 32 28 33 29 34 30 35 Breakfast / LunchBreakfast BUFFETS 37 28 24 27 23 26 22 25 21 24 20 23 19 22 exhibit hall 40 15 13 16 14 17 15 18 16 19 17 20 18 21 39 INNOVATION 14 12 13 11 12 10 11 9 10 8 9 7 8 EXHIBITORS CHALLENGE 36 38 FINALISTS 1 1 2 2 3 3 4 4 5 5 6 6 7 Partnering Check-in PARTNERING Forum Lunch BUFFETS Breakfast / Breakfast RESTROOM cocktail reception REGISTRATION content Welcome to RESI - - - - - - - - - - - - - - - 2 RESI Agenda - - - - - - - - - - - - - - - - - - 3 BOSTON RESI Innovation Challenge - - - - - - - 5 Exhibiting Companies - - - - - - - - - - 12 Track 1: Therapeutics Investor Panels - - - - - - - - - - - - - - - 19 Track 2: Device, Diagnostic, & HCIT Investor Panels - - - - 29 Track 3: Entrepreneur Workshops - - - - - - - - - - - - - - - - - - 38 Track 4: Asia-North America Workshop & Panels - - - - - - 41 Track 5: Partnering Forum - - - - - - - - - - - - - - - - - - - - - - - - 45 Sponsors & Media Partners - - - - - - - - - - - - - - - - - - - - - - - 46 1 welcome to resi On behalf of Life Science Nation (LSN) and our title sponsors WuXi AppTec and Johnson & Johnson Innovation JLABS, I would like to thank you for joining us at RESI Boston. LSN is very happy to welcome you all to Boston, the city where it all began, for our 14th RESI event.
    [Show full text]
  • Semi-Annual Market Review
    Semi-Annual Market Review HEALTH IT & HEALTH INFORMATION SERVICES JULY 2019 www.hgp.com TABLE OF CONTENTS 1 Health IT Executive Summary 3 2 Health IT Market Trends 6 3 HIT M&A (Including Buyout) 9 4 Health IT Capital Raises (Non-Buyout) 14 5 Healthcare Capital Markets 15 6 Macroeconomics 19 7 Health IT Headlines 21 8 About Healthcare Growth Partners 24 9 HGP Transaction Experience 25 10 Appendix A – M&A Highlights 28 11 Appendix B – Buyout Highlights 31 12 Appendix C – Investment Highlights 34 Copyright© 2019 Healthcare Growth Partners 2 HEALTH IT EXECUTIVE SUMMARY 1 An Accumulating Backlog of Disciplined Sellers Let’s chat about fireside chats. The term first used to describe a series of evening radio addresses given by U.S. President Franklin D. Roosevelt during the Great Depression and World War II is now investment banker speak for “soft launches” of sell-side and capital raise transactions. Every company has a price, and given a market of healthy valuations, more companies are testing the waters to find out whether they can achieve that price. That process now looks a little more informal, or how you might envision a fireside chat. Price (or valuation) discovery for a company can range from a single conversation with an individual buyer to a full-blown auction with hundreds of buyers and everything in between, including a fireside chat. Given the increasing share of informal conversations, the reality is that more companies are for sale than meets the eye. While the healthy valuations publicized and press-released are encouraging more and more companies to price shop, there is a simultaneous statistical phenomenon in perceived valuations that often goes unmentioned: survivorship bias.
    [Show full text]
  • Mbamission's Insider's Guide
    mbaMission’s Insider’s Guide The Wharton School University of Philadelphia Philadelphia, PA 2019–2020 presented by Applying to Business School? mbaMission is your partner in the process! Our team of dedicated, full-time admissions experts has helped thousands of applicants get into their dream MBA programs. These skilled storytellers and MBA graduates will work one-on-one with you to help you discover, select, and articulate your unique stories and stand out from the crowd. Why mbaMission? 15+ years of experience advising Ranked number one firm by GMAT tens of thousands of business Club and Poets&Quants school applicants Exclusively recommended by Extensive, unparalleled library of Services available for all stages of Manhattan Prep since 2009 supplementary content the application process Schedule a free, 30-minute consultation at www.mbamission.com/consult, and start getting answers to all your MBA admissions questions! +1-646-485-8844 [email protected] www.mbamission.com About mbaMission With our collaborative, full-time team of experienced advisors, mbaMission has elevated and professionalized the world of MBA admissions consulting, earning the exclusive recommendation of the world’s leading GMAT prep firms, Manhattan Prep and Kaplan GMAT, and hundreds more verified five-star reviews on GMAT Club than any other such firm. mbaMission prides itself on its high-touch client engagement model and robust library of free content that includes these Insider’s Guides as well as our Complete Start-to-Finish MBA Admissions Guide. Having already helped thousands of aspiring MBAs from around the world gain entry into elite US and international business schools, mbaMission continues to grow and improve in our quest to “graduate” additional classes of satisfied clients.
    [Show full text]
  • The View Beyond Venture Capital
    BUILDING A BUSINESS The view beyond venture capital Dennis Ford & Barbara Nelsen Fundraising is an integral part of almost every young biotech’s business strategy, yet many entrepreneurs do not have a systematic approach for identifying and prioritizing potential investors—many of whom work outside of traditional venture capital. re you a researcher looking to start a Why and how did the funding landscape During the downturns, it quickly became Anew venture around a discovery made change? apparent that entrusting capital to third-party in your laboratory? Perhaps you have already The big changes in the life science investor alternative fund managers was no longer an raised some seed money from your friends landscape start with the venture capitalist effective strategy, and investors began to with- and family and are now seeking funds to sus- (VC). In the past, venture capital funds were draw capital. The main reason for the with- tain and expand your startup. In the past, the typically capitalized by large institutional drawal (especially from VCs in the early-stage next step on your road to commercialization investors that consisted of pensions, endow- life science space) was generally meager returns would doubtless have been to seek funding ments, foundations and large family offices across the asset class; despite the high risk and from angels and venture capital funds; today, with $100 million to $1 billion in capital long lockup periods that investors accepted in however, the environment for financing an under management. Traditionally, the major- return for a promise of premium performance, early-stage life science venture looks strik- ity of these institutions maintained a low-risk, VCs were often not returning any more capital ingly different from that familiar landscape low-return portfolio of stocks and bonds that than investors would have earned by making of past decades.
    [Show full text]
  • CB-Insights Healthcare-Report-Q3
    In The Shadow Of Covid-19: Consumer InvestmentState Of Healthcare & Sector Q3’20 Trends Report: SectorTo Watch And Investment Trends To Watch 1 WHAT IS CB INSIGHTS? CB Insights helps the world’s leading companies make smarter technology decisions with data, not opinion. Our Technology Insights Platform provides companies with comprehensive data, expert insights and work management tools to drive growth and improve operations with technology. SIGN UP FOR A FREE TRIAL 2 With CB Insights, Froedtert Health is able to move quickly when assessing the market or evaluating potential partners. We can then dive deeper into a certain topic and collaborate across our organization all within one platform. Mike Anderes Chief Innovation and Digital Officer, Froedtert Health 3 8,000+ companies. 150 winners. 1 list. Digital Health 150 is here! Join Healthcare Managing Analyst, Ja Lee, for a behind the scenes tour of the list's development and trends it highlights. October 20th at 2pm EDT SIGN UP HERE FOR THE WEBINAR 1 The CBI Community DISCOUNTED TICKETS TO OUR UPCOMING OUR VIRTUAL EVENTS VIRTUAL EVENTS 4 Our Most Popular Client-Exclusive Research Digital Therapeutics: The $9B Market Redefining Disease Prevention, Management, & Treatment 9 Startups That Are Tackling Healthcare Interoperability Healthcare Anywhere: 120+ Telehealth Startups Transforming Patient Care 12 Startups Using Telehealth To Fill Gaps In Pandemic Care 9 Direct-To-Consumer Telehealth Startups To Watch Inside Google’s Ambitions To Become The Go-To Vendor For Healthcare IT 10 Startups
    [Show full text]
  • 1 NOTE: These Minutes Were Approved and Executed at the July
    NHRS Independent Investment Committee June 20, 2014 NOTE: These minutes were approved and executed at the July 18, 2014 Independent Investment Committee meeting. Independent Investment Committee June 20, 2014 Public Minutes New Hampshire Retirement System 54 Regional Drive Concord, NH 03301 Committee Members: Harold Janeway, Chair; David Jensen; Patrick O’Donnell; and Hersh Sosnoff. NHRS Trustees: Dean Crombie; Dick Gustafson, Ph.D; and Germano Martins. Staff: Larry Johansen, Director of Investments; Jack Dianis, Director of Finance; and Scott Needham, Investment Analyst. NEPC, LLC: Kevin Leonard, Partner and Senior Consultant; Sean Gill, Partner; and Charles Tedeschi, Senior Research Consultant. Mr. Janeway called the meeting to order at 9:03 a.m. On a motion by Mr. Jensen, seconded by Mr. O’Donnell, the Committee unanimously approved the public and non-public minutes of the May 23, 2014 Investment Committee meeting, as presented. Mr. Johansen referenced the “Investment Work Plan” dated May 27, 2014 and updated the Committee on several initiatives. He commented that NHRS was recently informed of the recent unexpected passing of Andrew Weiner, AllianceBernstein’s (“AB”) Director of Research for U.S. Small and Mid Cap Value. He indicated that staff has discussed the situation and AB’s related succession plan in detail with both NEPC and AB. He noted that James MacGregor, AB’s current Chief Investment Officer of Small and Mid Cap Value Equities previously served as Director of Research, and would assume those responsibilities on a temporary basis until AB appoints someone as Mr. Weiner’s successor. Mr. Johansen referenced the depth of AB’s research staff, and commented that the Value sleeve of the portfolio managed by AB on behalf of NHRS has outperformed its benchmark.
    [Show full text]
  • CED 2014 Innovators Report Hires
    INNOVATORS REPORT 2013 Trends in North Carolina Entrepreneurship 2013 IPO WATCH 226 NATIONAL 9 STATEWIDE 1. Aerie Pharmaceuticals 26 2. ChannelAdvisor SOUTHEAST 3. Chimerix 4. Heat Biologics 5. LipoScience 6. Ply Gem Holdings 7. Quintiles 8. Regado Biosciences 9. Stock Building Supply REPORT SOURCES: CED, National Venture Capital Association (NVCA), North Carolina Biotechnology Center, Ernst & Young, PricewaterhouseCoopers, SBIR.gov The Innovators Report is made possible by generous gifts to the CED Annual Fund. Thank you to our many supporters! For more information on how to contribute, please visit www.cednc.org/donate. MAJOR MERGERS & NC EVENTS ACQUISITIONS* DSM Pharmaceuticals Patheon $2.6 billion Santarus Salix Pharmaceuticals $2.6 billion COMPANY PRA International Kolberg, Kravis & Roberts $1.3 billion MILESTONES Solstas Lab Partners Quest Diagnostics $570 million Medicago Mitsubishi Tanabe Pharma $357 million Recognized as Advanced Liquid Logic Illumina $96 million 50 million Named Cracks a “Disrupter” sponsored 2013 Top 50 for the wireless Exam Design Pearson VUE app installs Fierce in Digital industry by Top 15 Health Entrepreneur Magazine Geomagic 3D Systems GrassRoots Biotechnology Monsanto Novella Clinical Quintiles Secure Enterprise Computing Agio Technology Axial Republic Appia Scioderm Exchange Wireless Tekelec Oracle ACQUIRED ACQUIRED BY *Partial listing DEALS & PARTNERSHIPS Signs up Yahoo! Sports, Bloomberg, CBS and Gannett $70 million deal with Toyama Chemical Company and a $58 million BARDA contact CHATHAM THERAPEUTICS
    [Show full text]
  • Life Sciences Venture Equity Market Review: the Evolving Role of Crossover Investors
    Life Sciences Venture Equity Market Review: The Evolving Role of Crossover Investors June 2021 Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. In Europe such services are offered through Torreya Partners (Europe) LLP, which is authorized and regulated by the UK Financial Conduct Authority. The Market for Equity Privates in Life Sciences TORREYA | PRIVATE LIFE SCIENCES VENTURE FINANCING MARKET REVIEW – JUNE 2021 2 Total Private Venture Financing Volume: 2000-2021 H1 Given volumes in the first half of this year, there is little doubt that 2021 will shape up to be the most active year in history for private financing activity in the life sciences sector. Total Volume of Private Biopharma, Diagnostics and Tools 50000 Financing Rounds by Year Jan 2000 - June 2021 600 (deals over $25mm, excluding medical devices, worldwide) 45000 523 500 40000 35000 373 400 356 30000 334 25000 300 20000 224 226 Transaction Transaction Count 184 200 15000 145 138 121 122 111 10000 109 88 97 96 81 72 100 Aggregate Aggregate Dollar Volume of Private Financings ($mm) 55 5000 40 35 23 0 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 H1 Transaction Count Dollar Volume ($mm) Source: Torreya analysis and records, CapitalIQ and Crunchbase TORREYA | PRIVATE LIFE SCIENCES VENTURE FINANCING MARKET REVIEW – JUNE 2021 3 Fresh Venture Capital Flowing into Life Science Sector We are on track to see record amount raised in life science venture capital in 2021.
    [Show full text]
  • Silicon Valley London Woodside Capital Partners (WCP)
    Silicon Valley London Woodside Capital Partners (WCP) proudly releases the inaugural healthcare report “State of Digital Health”. In 2016, healthcare cost in the US was $3.3 Trillion – 17.9% of GDP, passing $10,000 per capita mark for the first time ever. According to CMS, by 2026, the figure is projected to grow to $5.7 Trillion – 19.8% of GDP. The answer to curbing and reversing the trend with respect to healthcare costs lies in large part to the movement towards Digital Health, or ‘Health Tech’. The proliferation of devices and applications across the healthcare spectrum has led to a data tsunami – the “what”. Machine Learning, Artificial Intelligence and overall Big Data analytics are leading to real-time actionable insights – the “so what”. We have entered the realm of the Internet of Medical Things (IoMT), with ubiquitous connectivity and measurement of everything from our vitals and nutrition to physical activity and medical compliance. We are just starting to leverage that data in a meaningful way and seeing early impact on health and well-being. In 2017, venture investments in Digital Health startups exceeded $6 Billion for the first time, and the trend seems to be accelerating with $1.6 Billion invested in Q1, 2018. The juxtaposition of rising healthcare costs and increased Digital Health investments is not all that surprising. Advances in underlying real-time analytics and potential of leading edge innovations around genomics are turning the perceived fiction of personalized medicine into a real possibility. Foundational disruptions such as Blockchain, while relatively nascent, are creating excitement (and some anxiety) around secure, immutable data sharing across silos – with healthcare as the ideal use case.
    [Show full text]
  • Insurance Technology Four Trillion Dollar Industry Finally Goes Digital
    Insurance Technology Four Trillion Dollar Industry Finally Goes Digital Greg Roth, Partner Ben Howe, CEO Matei Sanders, Principal Catch the Wave . Insurance Technology is riding a wave of innovation and investment that is attempting to do in a few short years what the insurance industry itself has failed to do over the last decade: a complete digital migration across all business processes . With $4.6 Trillion in global annual premiums, or 5.6% of global GDP, the insurance industry is a highly attractive market where incumbents have been slow to embrace innovation . There are three competitive threats at work in the insurance market and they all point to Technology Disruption: (1) an explosion of well funded, InsureTech startups; (2) the feared entry of the B2C tech “titans” (i.e. Google, Amazon, Facebook, etc.); and (3) incumbents racing to adopt modern enabling technologies . Investors can sense the opportunity: InsureTech investments are up six-fold over the last five years across at all stages of funding . Whereas this first wave has primarily focused on distribution, a second wave is taking aim at how insurance products are designed, priced, and operated . Incumbents’ initial reaction has been to partner and invest mostly in enabling technology . These market forces point to increased M&A activity as customer demand will make InsureTech solutions key to an insurer’s customer acquisition and retention strategy (# of Private Insurance Tech Investments Ramping Placements) 200 173 150 122 100 91 63 46 50 28 0 2011 2012 2013 2014 2015 2016 Source: Capital IQ, CB Insights 2 Investment in Technology Pays Dividends Investment in Technology Translates to .
    [Show full text]
  • Global Venture Capital Funded Startups January 2018
    BUSINESS RESEARCH & CORPORATE INFORMATION SERVICES Global Venture Capital Funded Startups January 2018 **The information in this report is aggregated by the team at AM Research from various sources across the web. **The team at AMR tracks the global startup funding ecosystem closely and profiles thousands of VC firms and their portfolio startups. AM Research Services is a provider of desk research services to high growth startups and large global corporations. Kindly visit our website www.amresearch.in and contact us at [email protected] for any desk research requests, samples and quote. BUSINESS RESEARCH & CORPORATE INFORMATION SERVICES 10 Most Active Venture Capital Firms in January’ 2018 AM Research Services is a provider of desk research services to high growth startups and large global corporations. Kindly visit our website www.amresearch.in and contact us at [email protected] for any desk research requests, samples and quote. BUSINESS RESEARCH & CORPORATE INFORMATION SERVICES Breakout By Funding Rounds AM Research Services is a provider of desk research services to high growth startups and large global corporations. Kindly visit our website www.amresearch.in and contact us at [email protected] for any desk research requests, samples and quote. BUSINESS RESEARCH & CORPORATE INFORMATION SERVICES Series - A Funded Companies Amount Company Country Description Investors Raised CMAB was founded to provide international-standard development C-Bridge Capital and manufacturing services for CMAB BioBAY China biologic products. Our initial focus is $38 million Biopharma Inc I-Bridge Capital on pre-clinical and early-stage clinical Qianhai FoF (Phase I/II) products for customers in China and across the globe.
    [Show full text]